SUNZEN 0148
NORMAL

SUNZEN 0148

RM0.11

(6 customer reviews)
52 Weeks Range : 0.03 - 0.2

5 day volume Average = 1,033,520
20 day volume Average = 626,115
90 day volume Average = 490,791
Add to wishlistAdded to wishlistRemoved from wishlist 0
Add to compare
3.2/10 (Expert Score)
Stock is rated as #100 in category ACE Market
Hold Recommendation. Current price is fairly valued.
Prospective Profit
0.000
Assets
4.943
Dividend/ Cash
4.329
Liquidity
3.606
PROS:
  • Cash Rich Company
  • Low Gearing Ratio
CONS:
  • Making Huge Loss
  • Low Price-to-Tangible ratio
  • Poor Market Liquidity

klse: Sunzen Biotech Bhd


Corporate Information

Board   : Ace

Shariah : Non-Shariah Compliant

Sector   : Pharmaceuticals CPO

Address: No. 50, Jalan Anggerik Mokara,Kota Kemuning, Shah Alam, 40460, Selangor

Contact: +603-51229333

Website: https://www.sunzen.com.my/
 

Corporate Background

The business of the Sunzen Group began as a subsidiary of Pfizer, and changed its name to Sunzen Corporation in 1998 under a management buyout exercise. The company assumed its present name in 2007. Equipped with proven expertise in developing new animal health products, and leveraging on its marketing network in Malaysia and the region, the company is successfully developed and marketed animal health products under the “Sunzen” brand, as feed additives, nutritional feed supplements, veterinary pharmaceuticals, animal vaccines, and others: disinfectants, etc.

Forecast: SUNZEN 0148

Number of Share

535, 046, 088

Market Capital (RM)

58, 855, 070

Forecasted Profit or Loss (RM)

-8, 075, 826

Estimated Future EPS (sen)

-1.509

Perspective P/E ratio

-7.202

Estimated Dividend Yield (%)

0.184

Adjusted NTA (RM)

0.17

Result

Quarter Report History

Date Revenue,k PBT,k Net Profit,k
27/02/20 44,302 -14,804 -12,773
28/11/19 62,047 -3,170 -4,099
22/08/19 69,716 -1,506 -1,303
30/05/19 66,912 -1,070 -961
28/02/19 76,354 -7,774 -7,847
23/11/18 101,627 -1,555 -1,195
24/08/18 51,516 2,837 2,580
25/05/18 70,932 -449 -409
27/02/18 103,091 125 109
24/11/17 78,739 1,403 874
25/08/17 75,876 1,426 1,472
25/05/17 45,745 1,058 1,019

Fundamental

Fundamental Analysis

Last 4 Quarter Revenue (RM’000) 239,864
Last 4 Quarter Net Profit (RM’000) -19,156
Last 4 Quarter EPS (sen) -3.31
Last 4 Quarter PER
Last 4 Quarter Dividend (sen)
Last 4 Quarter Dividend Yield (%)
Net Tangible Assets (RM) 0.17
Goodwill (RM) 100
Cash (RM’000) 32,670
Debt (RM’000) 16,470
Total Debt (RM’000) 30,710
Net Assets (RM’000) 90,120
Current Ratio 5.13
Quick Ratio 4.11
Cash Ratio 2.67

Technical

Technical Analysis

MACD (26 vs 12) 0.001
Exponential Moving Average 5 0.086
Exponential Moving Average 20 0.085
Exponential Moving Average 90 0.086
Relative Strength Index 14 0.50
Stochastic %D 3 0.78
Stochastic %K 14 1.00

6 reviews for SUNZEN 0148

2.5 out of 5
0
0
4
1
1
Write a review
Show all Most Helpful Highest Rating Lowest Rating
  1. Investing Malaysia

    SUNZEN is forecasted to made loss of 3.57 millions, with an adjusted market capitalization of 60.81 millions

    Helpful(0) Unhelpful(0)You have already voted this
  2. Investing Malaysia

    Stock code of 0148 in Bursa Malaysia declared adjusted 0.22% dividend yield in past few years

    Helpful(0) Unhelpful(0)You have already voted this
  3. Investing Malaysia

    Sunzen Biotech Bhd gets a score of 18.25 in our stability test after the balance sheet, money statement study

    Helpful(0) Unhelpful(0)You have already voted this
  4. Investing Malaysia

    SUNZEN gets a score of 19.11 in our equity and assets quality test based on current share price of RM0.115

    Helpful(0) Unhelpful(0)You have already voted this
  5. Investing Malaysia

    Average investing volume for Sunzen Biotech Bhd in the past three months in stock market was 143.6k lots

    Helpful(0) Unhelpful(0)You have already voted this
  6. INVESTING MALAYSIA

    SUNZEN (6 JAN 20) Bursa Malaysia Securities Berhad (BMSB) has publicly reprimanded Sunzen Biotech Bhd and two of its executive directors for failing to obtain prior shareholders’ approval in respect of its diversification into a new business in the trading of crude palm oil (CPO) and its derivative products such as palm kernel and palm kernel shell in February 2017.

    Helpful(0) Unhelpful(0)You have already voted this

    Add a review

    Your email address will not be published. Required fields are marked *

    klse share price, target price, profit PER estimation
    Register New Account
    Name (required)
    Reset Password
    Compare items
    • Total (0)
    Compare